2026年3月26日，Kodiak Sciences宣布VEGF抗体聚合物Zenkuda治疗糖尿病性视网膜病变（DR）的三期临床GLOW2获得硬性结果。 受此消息影响，Kodiak Sciences当天股价大涨75%，市值达到24.6亿美元。

Investing.com - 奥本海默在Wave Life Sciences(NASDAQ:WVE)公司公布其1期INLIGHT研究的临床更新后,重申了其跑赢大盘评级和32.00美元的目标价。该目标价相较当前12.30美元的股价显示出上涨潜力,不过InvestingPro数据显示,根据其公允价值分析,该股票目前的估值可能偏高。 该研究评估了WVE-007,其中240毫克剂量组在六个月时显示内脏脂 ...

生命科学Life science在Trends in Biochemical Sciences创刊五十周年这个特别的时间节点，回顾本刊的创刊初衷与目标，令我倍受启发。1976年首期Trends in Biochemical Sciences[1]中，Bart van Tongeren提到，本刊的构想源于与国际生物化学联合会（International Union of Biochemistry, ...

Investing.com -- Kodiak Sciences Inc. (NASDAQ:KOD)股价周四上涨26%,此前该公司公布了GLOW2的积极顶线结果,这是其针对糖尿病视网膜病变治疗药物Zenkuda(tarcocimab tedromer ...

Life sciences organizations should modernize managed services now, focusing on operational readiness, outcome-based models, ...

WVE-007的安全性优势尤为明显，去年12月披露的数据也显示出一定的疗效潜力，但此次更新数据没有看到明确的量效关系，让资本市场对于INHBE siRNA的想象空间和热情有所下降。目前Arrowhead和Wave Life ...

Joel Mokyr, Philippe Aghion and Peter Howitt have been awarded the 2025 Nobel Prize in Economics. (Photo by Jonathan Nackstrand / AFP) / ALTERNATIVE CROP (Photo by JONATHAN NACKSTRAND/AFP via Getty ...

The subject area represents the next stage of the database’s evolution, and heralds other proposed changes to journal selection and article categorization. The first Nature Index tables in the applied ...

SHANGHAI, March 21 (Xinhua) -- China on Saturday published a high-quality journal list in the fields of medicine and life sciences, independently compiled by domestic institutions, offering a Chinese ...